Cyclopharm Appoints Nuclear Medicine Heavyweight as Incoming Chair
Cyclopharm secures nuclear medicine heavyweight as incoming Chair
Cyclopharm Limited (ASX: CYC) has appointed Doug Cubbin as Non-Executive Director, effective 4 May 2026. He will assume the role of Non-Executive Chair upon David Heaney’s retirement at the close of the company’s Annual General Meeting on 8 May 2026. The appointment represents a strategic leadership transition at a pivotal stage for the radiopharmaceutical company, securing an incoming Chair with direct experience navigating FDA approvals and US commercialisation — credentials directly relevant to Cyclopharm’s Technegas growth strategy in the United States.
Mr Cubbin brings over 20 years of leadership across nuclear medicine, radiopharmaceuticals, and regulated healthcare enterprises. He holds qualifications including GAICD, BBus (Acc), and FCPA, and is recognised for his governance expertise and capital markets acumen.
When big ASX news breaks, our subscribers know first
What makes Doug Cubbin’s experience valuable for Cyclopharm
ANSTO and radioisotope production expertise
Mr Cubbin is the former Executive Chairman of ANSTO Nuclear Medicine, where he led the establishment of the corporate vehicle that built and now operates Australia’s purpose-built $200 million radioisotope production facility. The facility is a globally significant asset capable of supplying approximately 25% of the world’s molybdenum-99 used in nuclear diagnostics. He also served as Executive General Manager and CFO of ANSTO, Australia’s national nuclear science agency, overseeing large-scale capital projects, international licensing arrangements, and government negotiations across a $1.5 billion asset base.
His experience spans the full nuclear medicine value chain, from isotope production and infrastructure investment through to commercial radiopharmaceutical development and global clinical deployment.
Telix Pharmaceuticals and FDA commercialisation track record
Mr Cubbin served as Group Chief Financial Officer of Telix Pharmaceuticals (ASX: TLX), joining the company before its IPO and remaining through its transformation into a global commercial business. During his tenure, he oversaw multiple acquisitions, international expansion, and, critically for Cyclopharm shareholders, the successful navigation of the FDA approval process and the commercial launch of Illuccix in the United States. Illuccix is now one of the world’s leading prostate cancer imaging agents.
This FDA and US commercialisation experience is directly applicable to Cyclopharm’s Technegas approval pathway and US market entry strategy, reducing execution risk for the company’s most significant growth opportunity.
Broader board and industry roles
Mr Cubbin’s industry credentials extend across multiple leadership positions:
- Chairman of Cyclotek Group, Australia’s largest PET radiopharmaceutical network
- Chairman of Oncosil Medical (ASX: OSL)
- Current board and executive roles with GAIASO Theranostics, focused on next-generation nuclear oncology platforms
He has built relationships spanning the breadth of the global nuclear medicine industry, from the world’s largest nuclear medicine companies through to emerging start-ups, providing him with a rare perspective on industry trends and the networks to help shape them.
| Role | Organisation | Relevance to Cyclopharm |
|---|---|---|
| Executive Chairman | ANSTO Nuclear Medicine | Radioisotope production, $200M facility infrastructure |
| Group CFO | Telix Pharmaceuticals (ASX: TLX) | FDA approval, US commercialisation of Illuccix |
| Chairman | Cyclotek Group | PET radiopharmaceutical network leadership |
| Chairman | Oncosil Medical (ASX: OSL) | ASX med-tech governance experience |
What is a Non-Executive Chair and why does it matter?
A Non-Executive Chair leads the board of directors and is responsible for governance, shareholder accountability, and strategic oversight, but does not hold operational responsibilities within the company. This role is separate from the Managing Director, who runs the company on a day-to-day basis.
This separation of responsibilities is a governance best practice. The Chair leads the board, sets the agenda for board meetings, and ensures directors fulfil their fiduciary duties. The Managing Director leads the executive team, implements strategy, and delivers operational outcomes. Strong governance frameworks support sustainable growth and provide institutional investors with confidence that the company is structured to manage risk and execute strategy effectively.
The appointment of an experienced, independent Chair with deep sector expertise signals board-level commitment to governance standards expected by institutional investors.
Leadership perspectives on the transition
David Heaney, Outgoing Non-Executive Chair
“Serving as Chair of Cyclopharm has been one of the most rewarding experiences of my career. I am immensely proud of what we have built together and the position the Company is in today. I leave knowing that Cyclopharm is in very good hands. Doug brings exceptional depth of experience in nuclear medicine and a proven track record of building global healthcare businesses at the highest level. The Board, the management team and our shareholders could not ask for a more capable or committed successor.”
Doug Cubbin, Incoming Non-Executive Chair
“I am genuinely excited to be joining the Cyclopharm Board at such a pivotal time for the Company. Cyclopharm’s Technegas technology occupies a unique and compelling position in the global nuclear medicine landscape, and the commercial opportunity, particularly in the United States, is significant. I look forward to working closely with James and the management team to accelerate that growth. The relationship between Chair and Managing Director is fundamental to any well-governed company, and I am confident that James and I will build a strong and productive working partnership in the best interests of shareholders.”
James McBrayer, Managing Director
“I have competed with Doug, conferred with Doug and partnered with Doug over many years in this industry. At every stage I respected him enormously, his judgement, his integrity and his ability to get things done at the very top of the global nuclear medicine industry. I am thrilled that he has joined our Board. His international experience will be a real asset as we grow in the United States and other markets. I know from experience that Doug brings out the best in the people around him, and I have no doubt he will do the same as Chair of Cyclopharm.”
McBrayer’s comments emphasise the working relationship between Chair and Managing Director, signalling alignment at the top of the company and mutual respect built over years of industry collaboration.
The next major ASX story will hit our subscribers first
What this means for Cyclopharm’s US growth strategy
Mr Cubbin’s appointment positions Cyclopharm for its next growth phase, particularly in the United States. His US commercialisation experience at Telix Pharmaceuticals is directly relevant to Technegas market entry, having lived through the exact regulatory and commercialisation journey Cyclopharm is pursuing. His international networks and relationships across the global nuclear medicine industry provide strategic value as the company navigates FDA pathways and establishes commercial infrastructure in its most significant market opportunity.
His capital markets acumen, honed through Telix’s IPO and subsequent transformation into a global commercial business, adds a further layer of strategic capability to Cyclopharm’s board. The incoming Chair has demonstrated he can build well-governed, science-driven healthcare enterprises capable of scaling globally, reducing execution risk for the US opportunity and providing institutional investors with confidence in the company’s governance and strategic direction.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop.